reports
HIGHCO: SHAREHOLDING
HIGHCO: SHAREHOLDING INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES Declaration pursuant to Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des marchés financiers (AMF) Date of settlementof informationTotal number of sharesNumber of shares without voting rights (*)Number of voting rights for threshold calculation (**)Number of actual voting rights (exercisable at shareholders’ meeting)February 28, 202620 455 4031 071 02822 226 55121 155 523January 31, 202620 455 4031 063 86522 224 54221 160 677December 31, 202520 ...
HighCo : déclaration mensuelle des droits de vote
HighCo : déclaration mensuelle des droits de vote INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS Déclaration au titre des articles L.233-8 II du Code de commerce et 223-16 du Règlement général de l’Autorité des marchés financiers Date d’arrêté des informationsNombre d’actions composant le capitalNombre d’actionsprivées de droits de vote (*)Nombre de droits de vote pour le calcul des seuils (**)Nombre de droits de vote exerçables28 février 202620 455 4031 071 02822 226 55121 155 52331 janvier 202620 455 4031 063 86522 224 54221 160 67731 décembre 202520 455 4031 061 579...
Luotea PLC - Managers' Transactions: Antti Niitynpää
Luotea PLC - Managers' Transactions: Antti Niitynpää Luotea PLCStock exchange release 6 March 2026 at 3:15 pm Luotea Oyj - Managers' Transactions: Antti Niitynpää ____________________________________________ Person subject to the notification requirement Name: Antti Niitynpää Position: Chief Executive Officer Issuer: Luotea Oyj LEI: 743700Z9Z54VGHZA0028 Notification type: INITIAL NOTIFICATION Reference number: 144836/15/16 ____________________________________________ Transaction date: 2026-03-03 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000592464 Natur...
Luotea Oyj - Johdon liiketoimet: Antti Niitynpää
Luotea Oyj - Johdon liiketoimet: Antti Niitynpää Luotea OyjPörssitiedote6.3.2026 klo 15:15 Luotea Oyj - Johdon liiketoimet: Antti Niitynpää __________________________________________ Ilmoitusvelvollinen Nimi: Antti Niitynpää Asema: Toimitusjohtaja Liikkeeseenlaskija: Luotea Oyj LEI: 743700Z9Z54VGHZA0028 Ilmoituksen luonne: ENSIMMÄINEN ILMOITUS Viitenumero: 144836/15/16 ____________________________________________ Liiketoimen päivämäärä: 2026-03-03 Kauppapaikka: NASDAQ HELSINKI LTD (XHEL) Instrumenttityyppi: OSAKE ISIN: FI4000592464 Liiketoimen luonne: HANKINTA Liiketoimien ...
Alpha Modus Secures Settlement in Ongoing AI Retail Technology Patent ...
Alpha Modus Secures Settlement in Ongoing AI Retail Technology Patent Enforcement Efforts CORNELIUS, N.C., March 06, 2026 (GLOBE NEWSWIRE) -- Alpha Modus, Corp. (“Alpha Modus” or the “Company”), a subsidiary of (“Alpha Modus”) (), today announced that it has resolved its patent infringement litigation against Brookshire Grocery Co. pending in the United States District Court for the Eastern District of Texas. The litigation involved allegations of infringement relating to Alpha Modus’s patented technologies covering real-time consumer behavior analysis, digital advertising systems, smar...
Aktietilbagekøbsprogram
Aktietilbagekøbsprogram Den 23. oktober 2025 igangsatte Fast Ejendom Danmark A/S (”Selskabet”) et aktietilbagekøbsprogram. Aktietilbagekøbet løber i perioden fra og med den 24. oktober 2025 til og med den 23. oktober 2026. I denne periode vil Selskabet købe egne aktier op til en maksimal værdi af 10,0 mio. kr. i et aktietilbagekøbsprogram efter bestemmelserne i EU’s forordning nr. 596/2014 af 16. april 2014 og EU’s forordning 2016/1052 om supplerende regler til forordning nr. 596/2014, den såkaldte ”Safe Harbour” metode, som værner børsnoterede selskaber og deres bestyrelse og direktion im...
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne M...
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company will showcase real‑world findings in Duchenne muscular dystrophy (DMD) through multiple pos...
Allarity Therapeutics Closes $20 Million Financing to Accelerate the A...
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization Extends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and CommercializationFinancing Structured as Non-Convertible Debt Financing TARPON SPRINGS, Fla., March 6, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differe...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), ...
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corpo...
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancerNew England Journal of Medicine published first-in-human rezatapopt data showing selective reactivation of mutant p53 in advanced solid tumorsRezatapopt New Drug Application submi...
NMI Holdings, Inc. to Participate at the RBC Global Financial Institut...
NMI Holdings, Inc. to Participate at the RBC Global Financial Institutions Conference on March 11th, 2026 EMERYVILLE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- , (NASDAQ:NMIH) announced today that Adam Pollitzer, the company’s President and Chief Executive Officer, and Aurora Swithenbank, Executive Vice President and Chief Financial Officer, will be participating at the RBC Global Financial Institutions Conference on March 11th in New York City. A presentation that may be referenced during the conference will be available on the company’s website at . About NMI Holdings, Inc.NMI Holding...
Brunswick Exploration annonce l’augmentation de la taille de son place...
Brunswick Exploration annonce l’augmentation de la taille de son placement privé sans courtier en vertu de la dispense pour financement de l’émetteur coté Ne pas distribuer aux services de fil de presse des États-Unis ni diffuser aux États-Unis MONTRÉAL, 06 mars 2026 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (, ; ) (« BRW » ou la « société ») est heureuse d’annoncer qu’en raison d’une forte demande de la part des investisseurs, elle a augmenté le produit brut maximum de son placement privé sans courtier précédemment annoncé, le faisant passer de 4 000 000 $ à 5 500 000 $ (le « plac...
VEON and JazzWorld Advance Pakistan’s Digital Financial Future with Ac...
VEON and JazzWorld Advance Pakistan’s Digital Financial Future with Acquisition of TPL Insurance Acquisition to further financial inclusion through integrated digital financial services ecosystem Dubai, New York and Karachi – March 6, 2026 – VEON Ltd. (Nasdaq: VEON, “VEON”), a global digital operator, today announced that its subsidiary Jazz International Holding Limited (“JIH”) has entered into a definitive agreement to acquire a controlling stake in TPL Insurance Limited (“TPL Insurance”), a publicly listed insurance firm in Pakistan. The transaction, which marks a new milestone for VEON...
C.M. Advises VisionWave of Joint Venture Initiative in India with Majo...
C.M. Advises VisionWave of Joint Venture Initiative in India with Major Industrial Manufacturing Group WEST HOLLYWOOD, Calif. and MODI’IN, Israel, March 06, 2026 (GLOBE NEWSWIRE) -- VisionWave Holdings, Inc. (Nasdaq: VWAV) (“VisionWave” or the “Company”) announced today that C.M. Composite Materials Ltd. (“C.M.”), together with its wholly owned subsidiary FBM Composite Materials Ltd., has entered into a Memorandum of Understanding (MOU) with a large industrial manufacturing group headquartered in India to explore the formation of a joint venture manufacturing platform for advanced aerospa...
Hurco Reports First Quarter Results for Fiscal Year 2026
Hurco Reports First Quarter Results for Fiscal Year 2026 INDIANAPOLIS, March 06, 2026 (GLOBE NEWSWIRE) -- Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the first fiscal quarter ended January 31, 2026. Hurco recorded a net loss of $3,468,000, or $0.54 loss per diluted share, for the first quarter of fiscal year 2026, compared to a net loss of $4,320,000, or $0.67 loss per diluted share, for the corresponding period in fiscal year 2025. Sales and service fees for the first quarter of fiscal year 2026 were $42,868,000, a decrease of $3,546,000, or 8%, compared to the corre...
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and P...
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025. Key Highlights: Regulatory Progress: Achieved positive clinical study results from the AD04-103 pharmacokinetics ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on March 2, 2026, the Compensation Committee of Taysha's Board of Directors granted one new employee restricted stock units (RSUs) representing 156,870 shares of the Company’s common stock and an opt...
Catheter Precision’s LockeT Suture Retention Device to be Featured in ...
Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at ISLAA 2026 FORT MILL, S.C., March 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture retention device will be highlighted during live procedural cases at the . The event, co-hosted by the Academy for Continued Healthcare Learning (ACHL) and ISLAA Foundation, will take place from March 5-6, 2026, at the Biltmore Hotel in Los Angeles, California. The ISLAA meeting is a ...
Brunswick Exploration Announces Upsized Non-Brokered Life Private Plac...
Brunswick Exploration Announces Upsized Non-Brokered Life Private Placement Not for Distribution to United States News Wire Services or for Dissemination in the United States MONTREAL, March 06, 2026 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (, ; ) (“BRW” or the “Corporation”) is pleased to announce that as a result of strong investor demand, it has increased the maximum gross proceeds of its previously announced non-brokered private placement from $4,000,000 to $5,500,000 (the “Offering”). The upsized Offering now consists of the sale of up to 22,000,000 units of the Corporation (...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.